Back20/20 Biolabs Common Stock Overview

20/20 Biolabs Common Stock Total Liabilities

Latest total liabilities for AIDX: $470K.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$466177.00

Peer average

Loading

20/20 Biolabs Common Stock Total Liabilities History

Loading

20/20 Biolabs Common Stock vs. peers: Total Liabilities Comparison

Loading

20/20 Biolabs Common Stock Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

20/20 Biolabs Common Stock (AIDX) FAQ

20/20 Biolabs Common Stock's total liabilities stands at $470K as of March 2026. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether 20/20 Biolabs Common Stock's total liabilities is expanding or contracting. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how 20/20 Biolabs Common Stock's total liabilities evolved across reporting periods, while the comparison chart places AIDX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.